Semper Paratus Acquisition Corp: directors' dealings · United States · SEC (Form 4)

About Semper Paratus Acquisition Corp

Semper Paratus Acquisition Corp was a U.S.-linked SPAC rather than a traditional operating business: a special purpose acquisition company created to pursue a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more operating businesses. SEC filings show the company was incorporated on April 21, 2021 as a Cayman Islands exempted entity, with principal executive offices at 767 Third Avenue, 38th Floor, New York, New York 10017, United States. Its original purpose was to raise capital on the U.S. public markets and identify a suitable acquisition target within the SPAC structure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001860871/000149315223042391/forms-4a.htm?utm_source=openai)) The company completed its IPO on November 8, 2021, raising $345 million in gross proceeds through 34.5 million units priced at $10.00 per unit, with each unit consisting of one Class A ordinary share and one-half of one warrant. That capital base is central to understanding the issuer’s economics: unlike an industrial or technology company, a SPAC’s value is driven by its trust account, its sponsor structure, and the quality of the eventual business combination rather than by recurring product revenues. In the U.S. market context, such vehicles are typically associated with Nasdaq or NYSE listings, and investors assess them primarily as event-driven situations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001860871/000149315223042391/forms-4a.htm?utm_source=openai)) From a corporate history perspective, Semper Paratus is most important for what happened next. SEC documents indicate that it entered into a merger agreement with Tevogen Bio Inc. in 2023, and the transaction closed on February 14, 2024, at which point Semper Paratus was renamed Tevogen Bio Holdings Inc. As a result, Semper Paratus should not be analyzed today as a standalone operating issuer with products or services of its own; instead, it is the pre-combination corporate shell and transaction history behind the current post-merger company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/2070887/000121390025062977/ea0242759-02.htm?utm_source=openai)) In competitive terms, Semper Paratus had no legacy operating line items, manufacturing footprint, or consumer-facing product portfolio. Its competitive position depended on sponsor credibility, deal sourcing, execution discipline, and the ability to complete a value-accretive merger before capital erosion from redemptions and extension costs became prohibitive. Recent notable developments therefore relate to the business combination process, sponsor/shareholder structure changes, and SEC filings, including the merger and related proxy materials, rather than product launches or market share trends. For international investors, the key takeaway is that this was a U.S.-listed SPAC story whose investment case hinged on transaction execution, dilution management, and the fundamentals of the acquired business after closing. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1860871/000149315223020433/form8-k.htm?utm_source=openai))